#ACR18 Late Breaking Abstracts #L17 Bimekizumab (anti-IL17 A & F) in PsA. Superior ACR50 vs PBO at wk 12, increase in response to wk24, sustained to wk48. No major new safety signals (candida 5%, LFTs, 1 suicidal ideation). Would be interesting to see vs IL17A alone. @RheumNow https://t.co/r41yRb55Y7